Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.

J Thorac Dis · 2023 · PMC10183556 · PMID 37197488

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Although there was no statistically significant difference in OS between the two groups (P=0.221), the subgroup analysis showed that patients in group A (mOS: 10.4, 95% CI: 0.3 to 20.6 months) exhibited a favorable trend in OS compared with group B (mOS: 18.0, 95% CI: 5.4 to 30.6 months) ( Figure 5B ).

also in 377 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.